Current update on Biotech-IgG Equity
Biotech-IgG Equity has faced an intense first six months where the main focus have been on establishing new T2Dx instruments in Sweden, Denmark and Norway, as well with our partner T2 Biosystem in the US. Although the Covid-19 pandemic has caused a great impact on our environment, we are pleased to announce that we have had a very positive increase on all divisions, although mainly in blood analysis, says Glenn Renhult, Chairman of the Board at Biotech-IgG Equity. Biotech-IgG Equity AB:s establishment on T2 Biosystems blood analysis instrumentDue to this day, Biotech has five T2Dx